Evogene (EVGN) Income from Non-Controlling Interests (2014 - 2026)
Evogene (EVGN) posted Income from Non-Controlling Interests of -$26000.0 for Q1 2026, up 42.22% sequentially from -$45000.0 in Q4 2025, and up 93.53% YoY from -$13434.4 in Q1 2025.
Evogene (EVGN) Income from Non-Controlling Interests (2014 - 2026) Analysis & Trends
Evogene has reported Income from Non-Controlling Interests for 10 years, with the latest figure at -$26000.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 93.53% year-over-year to -$26000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 151.94% YoY) and the FY2025 annual result came in at $658000.0, up 141.94% from the prior year.
- Income from Non-Controlling Interests improved to -$26000.0 in Q1 2026 per EVGN's latest filing, from -$45000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $1.3 million in Q3 2025 and troughed at -$933000.0 in Q2 2022.
- A 5-year average of -$365823.5 and a median of -$566000.0 in 2024 frame the typical range for Income from Non-Controlling Interests.
- The widest YoY moves for Income from Non-Controlling Interests: up 324.62% in 2025, down 2333.33% in 2025.
- Over 5 years, Income from Non-Controlling Interests stood at -$823000.0 in 2022, then climbed by 10.57% to -$736000.0 in 2023, then soared by 41.3% to -$432000.0 in 2024, then jumped by 89.58% to -$45000.0 in 2025, then jumped by 42.22% to -$26000.0 in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$26000.0, -$45000.0, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -26,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26,000.00 |
| Dec 31, 2025 | -45,000.00 |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | -219,000.00 |
| Mar 31, 2025 | -402,000.00 |
| Dec 31, 2024 | -432,000.00 |
| Sep 30, 2024 | -589,000.00 |
| Jun 30, 2024 | -566,000.00 |
| Mar 31, 2024 | 18,000.00 |
| Dec 31, 2023 | -736,000.00 |
| Sep 30, 2023 | 126,000.00 |
| Jun 30, 2023 | -755,000.00 |
| Mar 31, 2023 | -710,000.00 |
| Dec 31, 2022 | -823,000.00 |
| Sep 30, 2022 | -619,000.00 |
| Jun 30, 2022 | -933,000.00 |
| Mar 31, 2022 | -831,000.00 |
| Dec 31, 2021 | -713,000.00 |
| Sep 30, 2021 | -733,000.00 |
| Jun 30, 2021 | -688,000.00 |